LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Total research and development expenses | 14,645 | 16,744 | NaN |
| General and administrative expenses | 7,459 | 13,660 | NaN |
| Total operating loss | 22,104 | 30,404 | NaN |
| Non-operating income | 3,050 | 5,200 | NaN |
| Income tax provision | NaN | 1 | NaN |
| Net loss | -19,054 | -11,472 | -13,733 |
| Stock-based compensation expense | 2,566 | 2,341 | 1,850 |
| Shares issued for services rendered | NaN | 0 | 0 |
| Loss on write off of property and equipment | NaN | 8 | NaN |
| Write off of deferred offering costs | NaN | 0 | 0 |
| Depreciation and amortization | NaN | 321 | NaN |
| Depreciation | -154 | NaN | 236 |
| Noncash lease expense | 50 | 47 | 100 |
| Realized gain on sale of marketable securities, net | 0 | 0 | 119 |
| Amortization (accretion) of premium (discounts) on investments, net | -17 | -17 | -244 |
| Gain on change in fair value of derivative instruments | 200 | -401 | 1,562 |
| Prepaid expenses and other current assets | 10,219 | 11,297 | 1,042 |
| Operating lease liabilities | -99 | -98 | -36 |
| Accrued interest on marketable securities | 103 | -100 | -168 |
| Accounts payable and accrued expenses | 3,464 | 1,965 | -2,875 |
| Net cash used in operating activities | -23,290 | -18,103 | -17,105 |
| Purchases of property and equipment | 32 | 40 | 12 |
| Purchase of marketable securities | NaN | 0 | 44,836 |
| Proceeds from the sale of marketable securities | 0 | 0 | 2,501 |
| Maturities of marketable securities | 0 | 0 | 2,500 |
| Net cash (used in) provided by investing activities | -32 | -40 | -39,847 |
| Proceeds from initial public offering | NaN | 0 | 327,750 |
| Proceeds from issuance of common stock and pre-funded warrants in a private placement | 100,000 | NaN | NaN |
| Payment of issuance costs for initial public offering | NaN | 1,170 | 24,265 |
| Payment of issuance costs for private placement | 6,198 | NaN | NaN |
| Proceeds from exercise of warrants and options | 29 | 0 | 247 |
| Proceeds from issuance of redeemable convertible series c preferred stock | NaN | 0 | 0 |
| Payment of issuance costs for redeemable convertible series c preferred stock | NaN | 0 | 0 |
| Net cash provided by financing activities | 93,831 | -1,170 | 303,732 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 70,509 | -19,313 | 246,780 |
| Cash, cash equivalents and restricted cash, beginning of period | 250,943 | 270,256 | 23,476 |
| Cash, cash equivalents and restricted cash, end of period | 321,452 | 250,943 | 270,256 |